MaxCyte (MXCT) Investor presentation summary

Portfolio overview

• 11 SPL clients support durable revenue with 12 active clinical programs and 1 commercial program as of March 2026.

• 31 SPL agreements in place, with partners including Vertex, CRISPR Therapeutics, and Wugen.

• 14 active clinical trials span genetic diseases, blood cancers, solid tumors, and autoimmune diseases.

• SPL programs have generated over $30M in milestone payments, with $110M in precommercial milestone potential.

Clinical and commercial pipeline

• Vertex/CRISPR CASGEVY is the first approved product, launched in 2023 in the US and Europe.

• Five product candidates are set to enter pivotal studies within 6–18 months, with launch potential in 2027–2028.

• Seven additional products are in Phase 1, and 18 are in preclinical development, targeting launches beyond 2028.

• SPL clinical programs include both autologous and allogeneic cell approaches across multiple indications.

Growth and opportunity

• Number of clinical and commercial SPL programs and licensed partners has nearly doubled over the past five years.

• SPL trials are expanding across genetic diseases, blood cancers, solid tumors, autoimmune, and neurodegenerative diseases.

• Second wave of SPL programs is set to enter pivotal studies, focusing on hematologic malignancies and undisclosed indications.